المؤلفون: Raza Ur Rehman, MBBS, Ahmad Furqan Anjum, MBBS, Rida Fatima, MBBS

المصدر: Current Therapeutic Research, Vol 102, Iss , Pp 100773- (2025)

مصطلحات موضوعية: Bispecific T-cell engager, DLL3 protein, FDA approval, Immunotherapy, Small cell Lung cancer (SCLC), Tarlatamab, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0011393X24000432; https://doaj.org/toc/0011-393X

URL الوصول: https://doaj.org/article/1d17ff7c5f3f4df29652464ae10a9c8e

المؤلفون: Solange R. Paredes-Moscosso, Amit C. Nathwani

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: bispecific antibodies, PDAC, blinatumomab, solitomab, EpCAM BiTE, tarlatamab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1429330/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/3e55b8c436f24c83a9f9394d7ff120b8

المؤلفون: Alissa J. Cooper, MD, Natasha Rekhtman, MD, PhD, Marina K. Baine, MD, PhD, Marie C. Thomas, DNP, FNP-C, Alia C. Lynch, PharmD, BCOP, Ryan D. Gentzler, MD, MS

المصدر: JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100750- (2024)

مصطلحات موضوعية: Carcinoid, Neuroendocrine, Tarlatamab, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001206; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/a8288d90bce449ed811d1abf0dde896c

المؤلفون: Shetal A. Patel, MD, PhD, Young Whang, MD, PhD, Chaely Medley, NP, Kevin Chen, PharmD, Jasmine Jordan, BS, Dante Bortone, PhD, Benjamin Vincent, MD, PhD, Jared Weiss, MD

المصدر: JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100712- (2024)

مصطلحات موضوعية: Tarlatamab, Large cell neuroendocrine carcinoma, DLL3, Bispecific T-cell engager, Cytokine release syndrome, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000821; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/8000f77d3fd64147a7f544962cd9ad9f

المؤلفون: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

المصدر: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-21 (2023)

مصطلحات موضوعية: DLL3, Small cell lung cancer, T-cell engager, Antibody-drug conjugate, Tarlatamab, AMG 757, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1756-8722

URL الوصول: https://doaj.org/article/10e1da2e3d234f1e801863a73f93ec88

المؤلفون: Diego Luigi Cortinovis, Francesca Colonese, Maria Ida Abbate, Luca Sala, Marco Meazza Prina, Nicoletta Cordani, Elisa Sala, Stefania Canova

المصدر: Frontiers in Medicine, Vol 9 (2022)

مصطلحات موضوعية: DLL3, small-cell lung cancer, rovalpituzumab tesirine, tarlatamab, molecular classification, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2022.989405/full; https://doaj.org/toc/2296-858X

URL الوصول: https://doaj.org/article/ff2a9ec9aff845d988eed6fe167cecde

المؤلفون: Ahn, Hyung-Min, Park, Seog-Yun, Choi, Yura, Kim, Jaemin, Lee, Youngjoo

المصدر: Drug Resist Updat ; ISSN:1532-2084 ; Volume:79

مصطلحات موضوعية: DLL3, Drug resistance, NOTCH, Small cell lung cancer, Tarlatamab

Relation: https://doi.org/10.1016/j.drup.2024.101198; https://pubmed.ncbi.nlm.nih.gov/39742708

الاتاحة: https://doi.org/10.1016/j.drup.2024.101198
https://pubmed.ncbi.nlm.nih.gov/39742708

المؤلفون: Lorenzo Ávila, Vianney

المساهمون: Garrido López, María Pilar, Olmedo García, María Eugenia, Universidad de Alcalá. Facultad de Medicina y Ciencias de la Salud

مصطلحات موضوعية: Cáncer de pulmón, Cáncer de pulmón de células pequeñas, PD-L1, DLL3, Inmunoterapia, Microambiente, Lurbinectidina, Tarlatamab, Anticuerpo biespecífico, Small cell lung cancer, ADC, Immunotherapy, Microenvironment, Lurbinectedin, Bispecific antibody, Medicina, Medicine

وصف الملف: application/pdf

Relation: Lorenzo Ávila, Vianney. Carcinoma de pulmón de células pequeñas en el siglo XXI. Trabajo Fin de Grado/Máster. Universidad de Alcalá, 2024; http://hdl.handle.net/10017/62506

الاتاحة: http://hdl.handle.net/10017/62506

المؤلفون: Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Meazza Prina, M, Cordani, N, Sala, E, Canova, S, Cortinovis D. L., Colonese F., Abbate M. I., Sala L., Meazza Prina M., Cordani N., Sala E., Canova S.

مصطلحات الفهرس: DLL3, molecular classification, rovalpituzumab tesirine, small-cell lung cancer, tarlatamab, info:eu-repo/semantics/article

URL: https://hdl.handle.net/10281/406056
info:eu-repo/semantics/altIdentifier/pmid/36530878
info:eu-repo/semantics/altIdentifier/wos/WOS:000898365700001
volume:9
journal:FRONTIERS IN MEDICINE